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Little is known about the prophylactic use of recombinant factor VIIa (rFVIIa) in patients undergoing surgery for a 
bleeding aorta employing cardiopulmonary bypass. We report the successful use of rFVIIa in a patient undergoing 
hypothermic circulatory arrest and prolonged cardiopulmonary bypass for repair of a DeBakey type III aortic 
dissection.  (Korean J Anesthesiol 2011; 61: 431-434)
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CC
Recombinant factor VIIa (rFVIIa) was developed to treat 
bleeding episodes in patients with hemophilia A or B who have 
inhibitors of factor VIII or IX and in patients with acquired 
hemophilia. At present, rFVIIa is also used for hemostatic 
resuscitation of severe trauma patients, and those with 
refractory bleeding during cardiac surgery [1-3] and post-
operative hemorrhage. The use of rFVIIa as a prophylactic agent 
has been limited, because of concerns about the possibility 
of thrombosis and because of the high cost of rFVIIa. Thus, 
little is known about the prophylactic use of rFVIIa in patients 
undergoing surgery for an aortic hemorrhage [4]. We describe 
here the prophylactic use of rFVIIa in a patient undergoing 
hypothermic circulatory arrest and prolonged cardiopulmonary 
bypass for repair of a DeBakey type III aortic dissection.
Case Report
A 62-year-old man (175 cm, 68 kg), confirmed as having 
aortic dissection type III, presented for aortic surgery. Computed 
tomography showed that the dissection would extend from his 
subclavian artery to the level of his renal artery. 
Before the induction of general anesthesia, an intra-
arterial catheter was inserted into his radial artery under local 
anesthetic. General anesthesia was induced with etomidate 
12 mg iv and rocuronium 50 mg iv and maintained with a 
continuous infusion of propofol (effect site concentration 1.0-
2.0 ug/ml) and remifentanil (effect site concentration 9-16 ng/
ml) using a target controlled infusion pump (Orchestra
Ⓡ Base 
Primea, Fresenius Vial, Brezins, France). Hypnotic depth was 
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assessed using a bispectral index monitor (BIS, A-2000, Aspect 
Medical Systems, Natick, MA, USA). A continuous infusion of 
rocuronium 30 mg/h was started. After tracheal intubation, 
with a double lumen tube for thoracotomy, his lungs were 
mechanically ventilated with 100% oxygen. Lumbar drainage 
was inserted at L3-4 level to drain cerebrospinal fluid (CSF), 
thus controlling intracranial pressure and maintaining CSF 
pressure at 8 to 10 mmHg. After iv injection of heparin 2000 IU, 
a central venous catheter (Arrow-Howes
TM Large-Bore, Arrow
Ⓡ 
International Inc, Reading, PA, USA) and a superior vena cava 
cannula (DLP
TM Femoral Arterial Cannula, 17 Fr, Medtronic 
Inc, Minneapolis, MN, USA) were inserted through the right 
subclavian vein and right internal jugular vein, respectively. 
A second central venous catheter (Arrow-Howes
TM, 7.5 Fr, 
3 Lumen, Arrow
Ⓡ International Inc, Reading, PA, USA) was 
inserted through the left subclavian vein. We monitored five-
lead electrocardiography, pulse oximetry, capnography, urine 
output, electroencephalography (EEG) and cerebral oximetry 
(SOMANETICS
Ⓡ INVOS OXIMETER, Troy, MI, USA). A cell 
salvage device (AUTOLOG
TM, Medtronic Inc, Minneapolis, MN, 
USA) was used, and salvaged blood was reinfused before the 
end of surgery. 
During cardiopulmonary bypass (CPB), activated clotting 
time (ACT) was maintained at >480 seconds with an initial 
heparin dose of 300 IU/kg and 3 additional doses of total 16,000 
IU each. At a systemic temperature of 17.5
oC, achieving a flat 
EEG and a bispectral index of 0, total circulatory arrest was 
allowed for 18 minutes. Total CPB time was 248 minutes, and 
cross-clamp time was 75 minutes. During CPB, the patient 
received 1,500 ml of plasma as priming solution, followed by 
1,400 ml packed red blood cells (P-RBC), 3,000 ml of plasma and 
1,000 ml of half-saline, administered by a CPB machine. After 
uneventful weaning from CPB, the patient was administered 4.5 
mg/kg of protamine to reverse the effects of heparin and return 
the ACT to its preoperative level, 122 seconds.
At this point, his prothrombin time (PT) was 18.8 seconds, 
his international normalized ratio (INR) was 1.66 and his 
activated partial thrombin time (aPTT) was 40.1 seconds. 
Complete blood count (CBC) showed that his hemoglobin 
concentration was 12.1 g/dl and his platelet count was 74,000/
mm
3. Rotational thromboelastometry (ROTEM Analyser, Tem 
International GmbH, Munich, Germany) showed a clotting time 
(CT) of 359 seconds, a clot formation time (CFT) of 290 seconds, 
an α angle of 47
o, a maximum clot firmness (MCF) of 43 mm, 
and a maximum lysis (ML) of 100% (Fig. 1). Ten minutes after 
prophylactic administration of 240 kIU (4.8 mg) rFVIIa, his 
PT was 13.5 seconds, his INR was 1.19 and his aPTT was 40.3 
seconds. ROTEM showed a CT of 216 seconds, a CFT of 257 
Table 1. CBC and Coagulation Profiles
After protamine
After 240 KIU 
rFVIIa
After FFP, PC
At the end of 
surgery




















































Fig. 1. ROTEM (INTEM). (A) After protamine administration. CT 359, CFT 290, α 47
o, MCF 43 mm, ML 100%. (B) After rFVIIa administration. CT 
204, CFT 267, α 48
o, MCF 43 mm, ML 23%. CT: clotting time. CFT: clot formation time. α: α-angle. MCF: maximum clot firmness. ML: maximum lysis.433 www.ekja.org
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seconds, an α angle of 49
o, an MCF of 43 mm, and an ML of 18% 
(Fig. 1). Before obtaining the latter set of coagulation results, we 
had administered 2 units of P-RBC, 5 units of FFP, and 10 units 
of platelet concentrates to treat the anticipated coagulopathy. 
No additional rFVIIa or blood products were required. At the 
end of surgery, CBC showed a hemoglobin concentration of 
12.7 g/dL and a platelet count of 118,000/mm
3. Coagulation 
profile revealed a PT of 12.2 seconds, an INR of 1.08 and an 
aPTT of 34.3 seconds (Table 1). The total surgical time was 602 
minutes; fluids administered included 1,500 ml normal saline, 
1,500 ml synthetic colloid, 2 units of P-RBC (plus 7 units during 
CPB), 5 units of FFP, 10 units of PC, 1,300 ml saved blood, and 
800 ml pump blood. Urine output was 1,950 ml, and expected 
blood loss was 3,780 ml.
In the ICU, no blood products were required to maintain 
hemo  globin or coagulation level. During the first few hours, 
the chest tubes drained 50-130 ml/h, later decreasing to 0-30 
ml/h. On postoperative day 1, the patient was weaned from 
the ventilator. On postoperative day 2, however, the patient’s 
mental state was drowsy and he was reintubated due to poor 
expectoration. At that time, CBC revealed a hemoglobin 
concen  tration of 11.7 g/dl and a platelet count of 174,000/mm
3. 
His PT was 13.1 seconds, his INR was 1.15 and his aPTT was 
29.2 seconds. On postoperative day 3, the patient’s mental state 
became alert, allowing extubation. The patient was moved to 
the general ward on postoperative day 6 and discharged, with 
no complications, on postoperative day 17. 
Discussion
Most repairs of aortic dissection involve large amounts 
of bleeding, despite improvements in surgical technique. 
Bleeding results from various interrelated factors, including the 
extent of surgical dissection, the use of anticoagulant for CPB, 
ischemia and reperfusion, fibrinolysis and dilution of platelets 
and coagulation factors. In this patient, the aortic dissection 
was widely extended, and both CPB and deep hypothermic 
circulatory arrest (DHCA) were required. We therefore decided 
to use rFVIIa to prevent large amounts of bleeding. In most 
centers, however, rFVIIa is used primarily when standard 
coagulation interventions have failed to control blood loss [2,5-7], 
even in the absence of definitive guidelines for the use of rFVIIa 
in cardiac surgery. 
Prophylactic rFVIIa has also been used in individuals 
with normal coagulation profiles who underwent retropubic 
prostatectomy with an expectation of massive perioperative 
bleeding [8]. That study showed that an injection of rFVIIa could 
reduce perioperative blood loss and eliminate the need for 
transfusion in patients undergoing major surgery. Prophylactic 
use of rFVIIa during orthotopic liver transplantation was 
found to significantly reduce the number of patients requiring 
RBC transfusion, with no increase in thromboembolic events 
compared with placebo [9]. In addition, rFVIIa was used to 
manage hemostasis in a Jehovah’s Witness [4].
Recombinant FVIIa was originally developed to manage 
bleeding in patients with hemophilia. In normal individuals, 
<1% of plasma rFVII is in the form rFVIIa. When rFVIIa is 
administered, it complexes with tissue factors at the injured 
vascular site; the resulting complex, in turn, initiates the 
coagulation cascade. rFVIIa also directly activates factor X on 
the surfaces of activated platelets independent of factor VIII 
and IX. The main hemostatic effect of rFVIIa is to increase the 
rate of thrombin generation. Therefore, rFVIIa can improve 
coagulation profiles and clot formation time. Indeed, we found 
that the coagulation profiles in our patient improved before 
administration of plasma products and platelets (Table 1). 
Many patients with massive bleeding suffer from fibrinolysis 
due to consumption of fibrinogen. Although aprotinin can 
reduce fibrinolysis, this agent is rarely used in cardiac surgery 
due to its association with high rates of renal failure, myocardial 
infarction or heart failure and stroke or encephalopathy [10]. 
rFVIIa was found to simultaneously accelerate clot formation 
and inhibit fibrinolysis by activating thrombin activatable 
fibrinolysis inhibitor (TAFI). Therefore, rFVIIa seems to 
eliminate the need for an additional antifibrinolytic agent such 
as aprotinin, tranexamic acid and aminocaproic acid. In our 
patient, ROTEM showed dramatically improved maximum lysis, 
from 100% to 23%, in the INTEM test. 
Prior to administration of rFVIIa, fibrinogen concentration 
should be >50 mg/dl, platelet count should be >50,000/mm
3 
and pH should be ≥7.1. At the time of rFVIIa administration 
to our patient, pH was 7.28, while platelet count, INR and 
aPTT were within their recommendation ranges (Table 1). 
Independent predictors of failure to respond to rFVIIa were 
found to include pretreatment abnormal coagulation tests (INR 
> 2.0, aPTT > 60 seconds, fibrinogen <100 mg/dl or platelet 
count < 80,000) [3], although others have reported that pH, 
platelet level, and fibrinogen level were not associated with 
response [2]. 
The most serious complications of rFVIIa are thrombo-
em  bolic. These complications are very rare in hemophilia 
patients and those with congenital or acquired factor VIII or IX 
inhibitors [11]. Most patients who undergo aortic dissection are 
atherosclerotic. They may have vulnerable plaques especially in 
coronary and cerebral arteries, which can trigger the extrinsic 
coagulation pathway during surgery. Therefore, if rFVIIa acts 
locally, ischemic events can activate these arteries. Monocytes 
are activated during and after CPB, and these monocytes are the 
main source of TF expression [12,13]. Adding rFVIIa may result 
in both local and systemic TF activation and finally promote 434 www.ekja.org
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thrombotic complications.
Despite concerns about thrombosis, rFVIIa has some 
benefits in cardiac surgery. These include improvements in 
coagulation profiles, reduced volumes of transfusion products 
and transfusion related complications, and rescue hemostasis 
in case of intractable bleeding during cardiac surgery. Although 
rFVIIa is being used primarily when standard interventions 
have failed to control blood loss [3], prophylactic use of rFVIIa 
may have efficacy and safety. Another issue related to rFVIIa is 
the cost-effectiveness in its off-label use. The official price for 
120 kIU of rFVIIa is ￡1410. Although rFVIIa is cost-effective in 
hemophilia patients [14,15], the cost effectiveness of its off-label 
use in cardiac surgery has not been determined, especially as a 
prophylactic agent.
In conclusion, we found that prophylactic use of rFVIIa in 
a patient undergoing aortic dissection resulted in a favorable 
outcome and safety of the operation. This single case report, 
however, could not determine whether use of rFVIIa in a major 
operation is more beneficent or harmful. That determination 
requires large-scale controlled clinical trials to evaluate the 
efficacy and safety of this treatment. 
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